
Reta-PeptideSS-31
Ordered SS-31 from Reta-Peptide? Mail in a sample (US only) and let us test it.
Test my supplyReta-Peptide SS-31 has a mixed purity-focused profile, with misses at 98.7% in April and 99.4% on the latest November test. Identity passed throughout and fill stayed within this method's window, making purity volatility the main signal.
Echemi records, RDAP, and archived policies point to a China-centered trading operation behind a U.S.-listed brand, with the legal counterparty still unresolved. The report maps Reta-Peptide to Retalux, Peptaura batch tokens, lookalike domains, and direct-payment gaps.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Reta-Peptide rows.
Cancel anytime
About Reta-Peptide test results from Finnrick
Reta-Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 15 peptides and 273 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Reta-Peptide peptides in this dataset are BPC-157 (21 tests), Cagrilintide (4 tests) and CJC-1295 (9 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests. It also includes 1 correction related to this vendor.
Ordered SS-31 from Reta-Peptide? Mail in a sample (US only) and let us test it.
Test my supply